Background: Cabozantinib is approved, in various settings, for the treatment of renal cell
carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been …

At present, studies have found that c-Met is mainly involved in epithelial-mesenchymal
transition (EMT) of tumor tissues in urologic neoplasms. Hepatocyte growth factor (HGF) …

Background Real-world data on cabozantinib in metastatic renal cell carcinoma (mRCC) is
limited. This study (CABOREAL) reports treatment patterns and outcomes for patients treated …

Background Cabozantinib is a tyrosine kinase inhibitor with a substantial efficacy in
metastatic renal cell carcinoma, and is associated with a challenging toxicity profile leading …

Aim In the registration trial, cabozantinib exposure≥ 750 ng/mL correlated to improved
tumor size reduction, response rate and progression free survival (PFS) in patients with …

Background Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on
the METEOR and CABOSUN trials. However, real‐world effectiveness and dosing patterns …

Aims Gastric cancer (GC) is one of the most common malignant tumors in the world. Anti-
angiogenic therapy is a useful strategy for the treatment of advanced GC. This study was …

Background Cabozantinib showed efficacy and manageable toxicity in patients with
metastatic renal cell carcinoma (mRCC). In this study we aimed to describe the safety and to …

Background Cabozantinib is an approved treatment for metastatic renal cell carcinoma
(mRCC). This report presents an analysis of the safety profile and efficacy of cabozantinib in …

Over the past decade, the prognosis of advanced thyroid cancer (TC) patients has
dramatically improved thanks to the introduction of tyrosine kinase inhibitors (TKIs). Despite …